Platelets and Diabetes

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-319-47462-5_82
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Microparticles as new markers of cardiovascular risk in diabetes and beyond

  2016cited by this paper
• State-of-the-Art: Hypo-responsiveness to Oral Antiplatelet Therapy in Patients with Type 2 Diabetes Mellitus

  2015cited by this paper
• The Role of Tissue Factor in Atherothrombosis and Coronary Artery Disease: Insights into Platelet Tissue Factor

  2015cited by this paper
• Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus.

  2015cited by this paper
• Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome.

  2015cited by this paper
• Glycated Albumin With Loss of Fatty Acid Binding Capacity Contributes to Enhanced Arachidonate Oxygenation and Platelet Hyperactivity: Relevance in Patients With Type 2 Diabetes

  2014cited by this paper
• Abstract 17186: In Vivo Platelet Activation in Impaired Glucose Tolerance and During Progression of Type 2 Diabetes: a Cross-sectional and Longitudinal Study

  2014cited by this paper
• Circulating Dickkopf‐1 in Diabetes Mellitus: Association With Platelet Activation and Effects of Improved Metabolic Control and Low‐Dose Aspirin

  2014cited by this paper
• Inflammation in Atherosclerosis

  2012cited by this paper
• Platelet Isoprostane Overproduction in Diabetic Patients Treated With Aspirin

  2012cited by this paper
• Tissue factor and atherosclerosis: not only vessel wall-derived TF, but also platelet-associated TF.

  2012cited by this paper
• Diabetes mellitus and thrombosis.

  2012cited by this paper
• The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low‐dose aspirin in patients with and without diabetes

  2012cited by this paper
• Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients.

  2012cited by this paper
• Soluble CD36− a marker of the (pathophysiological) role of CD36 in the metabolic syndrome?

  2011cited by this paper
• Secondary prevention of stroke: can we do better than aspirin?

  2010cited by this paper
• Review article: Platelet abnormalities in diabetes mellitus

  2010cited by this paper
• Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus

  2010cited by this paper
• Nutraceuticals in diabetes and metabolic syndrome.

  2010cited by this paper
• Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes: A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation

  2010cited by this paper
• Circulating soluble CD36 is associated with glucose metabolism and interleukin-6 in glucose-intolerant men

  2009cited by this paper
• Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease.

  2009cited by this paper
• Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin

  2009cited by this paper
• Platelet is a major contributor to circulating levels of Dickkopf‐1: clinical implications in patients with multiple myeloma

  2009cited by this paper
• Role of platelets in atherothrombosis.

  2009cited by this paper
• Atherogenesis and atherothrombosis--focus on diabetes mellitus.

  2009cited by this paper
• Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".

  2009cited by this paper
• Nephropathy in Type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity

  2009cited by this paper
• Advanced glycation end products strongly activate platelets

  2009cited by this paper
• Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept

  2009cited by this paper
• Dynamic role of microparticles in type 2 diabetes mellitus.

  2009cited by this paper
• Soluble forms of RAGE in human diseases: clinical and therapeutical implications.

  2009cited by this paper
• The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases

  2009cited by this paper
• A Specific CD36-Dependent Signaling Pathway Is Required for Platelet Activation by Oxidized Low-Density Lipoprotein

  2008cited by this paper
• Oxidative stress and platelets.

  2008cited by this paper
• Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

  2008cited by this paper
• Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients.

  2008cited by this paper
• Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.

  2008cited by this paper
• Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects

  2008cited by this paper
• Level, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome

  2008cited by this paper
• Platelet-leukocyte interactions in inflammation and atherothrombosis.

  2007cited by this paper
• Platelet activation and atherothrombosis.

  2007cited by this paper
• The clot thickens—oxidized lipids and thrombosis

  2007cited by this paper
• WNTS and WNT receptors as therapeutic tools and targets in human disease processes.

  2007cited by this paper
• Reticulated platelets and uninhibited COX‐1 and COX‐2 decrease the antiplatelet effects of aspirin

  2007cited by this paper
• Malaria's journey through the lymph node.

  2007cited by this paper
• Soluble RAGE in type 2 diabetes: association with oxidative stress.

  2007cited by this paper
• Endogenously generated reactive oxygen species reduce PMCA activity in platelets from patients with non-insulin-dependent diabetes mellitus

  2006cited by this paper
• Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.

  2006cited by this paper
• Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study.

  2006cited by this paper
• Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes.

  2006cited by this paper
• Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.

  2006cited by this paper
• Abstract 265: Insulin Resistance as a Determinant of Platelet Activation in Obese Women

  2006cited by this paper
• Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.

  2006cited by this paper
• Advanced glycation end products: sparking the development of diabetic vascular injury.

  2006cited by this paper
• The mean platelet volume in subjects with impaired fasting glucose

  2006cited by this paper
• Analysis of gene and protein expression during monocyte-macrophage differentiation and cholesterol loading--cDNA and protein array study.

  2005cited by this paper
• Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy.

  2005cited by this paper
• P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes.

  2005cited by this paper
• Platelet Inhibition by Insulin Is Absent in Type 2 Diabetes Mellitus

  2005cited by this paper
• Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).

  2005cited by this paper
• Isoprostane formation and inhibition in atherothrombosis.

  2005cited by this paper
• Effects of Vitamin E Supplementation on Intracellular Antioxidant Enzyme Production in Adolescents with Type 1 Diabetes and Early Microangiopathy

  2004cited by this paper
• Circulating Oxidized Low-Density Lipoprotein and Its Association With Carotid Intima-Media Thickness in Asymptomatic Members of Familial Combined Hyperlipidemia Families

  2004cited by this paper
• Mean platelet volume in Type 2 diabetic patients.

  2004cited by this paper
• Improved metabolic control decreases platelet activation markers in patients with type‐2 diabetes

  2004cited by this paper
• IRS-1 Mediates Inhibition of Ca2+ Mobilization by Insulin via the Inhibitory G-protein Gi*

  2004cited by this paper
• Inflammation in the Prediabetic State Is Related to Increased Insulin Resistance Rather Than Decreased Insulin Secretion

  2003cited by this paper
• Enhanced Lipid Peroxidation and Platelet Activation in the Early Phase of Type 1 Diabetes Mellitus: Role of Interleukin-6 and Disease Duration

  2003cited by this paper
• Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus.

  2003cited by this paper
• Differential Regulation of Early Growth Response Gene-1 Expression by Insulin and Glucose in Vascular Endothelial Cells

  2003cited by this paper
• Platelet Activation Induces Cell-Surface Immunoreactive Tissue Factor Expression, Which Is Modulated Differently by Antiplatelet Drugs

  2003cited by this paper
• Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus

  2003cited by this paper
• Platelets and antiplatelet therapy in patients with diabetes mellitus.

  2003cited by this paper
• Molecular motors

  2003cited by this paper
• Platelet activation in obese women: role of inflammation and oxidant stress.

  2002cited by this paper
• Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function.

  2002cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Novel clinical markers of vascular wall inflammation.

  2001cited by this paper
• Platelet dysfunction in type 2 diabetes.

  2001cited by this paper
• The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses.

  2001cited by this paper
• Oxidative stress in diabetic nephropathy: Basic and clinical information

  2001cited by this paper
• Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction.

  2001cited by this paper
• Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes

  2001cited by this paper
• The role of platelets in diabetes-related vascular complications.

  2000cited by this paper
• The DECODE study. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe.

  2000cited by this paper
• Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.

  1999cited by this paper
• CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta.

  1999cited by this paper
• In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation.

  1999cited by this paper
• Insulin-induced expression of prostacyclin receptors on platelets is mediated through ADP-ribosylation of Gi alpha protein.

  1998cited by this paper
• Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction

  1997cited by this paper
• Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.

  1997cited by this paper
• Isoprostanes: potential markers of oxidant stress in atherothrombotic disease.

  1997cited by this paper
• Hyperinsulinemia as an independent risk factor for ischemic heart disease.

  1996cited by this paper
• Platelet size: measurement, physiology and vascular disease.

  1996cited by this paper
• Impaired Insulin-Induced Platelet Antiaggregating Effect in Obesity and In obese NIDDM Patients

  1995cited by this paper
• Elevated Levels of Authentic Plasma Hydroperoxides in NIDDM

  1995cited by this paper
• Reduced Plasma Peroxyl Radical Trapping Capacity and Increased Susceptibility of LDL to Oxidation In Poorly Controlled IDDM

  1994cited by this paper
• Platelet Abnormalities in Diabetes Mellitus

  1992cited by this paper
• Large Platelets Circulate in an Activated State in Diabetes Mellitus

  1991cited by this paper

• Platelets in Healthy and Disease States: From Biomarkers Discovery to Drug Targets Identification by Proteomics

  2020influential citation